Investment Analysts’ Weekly Ratings Changes for Incyte (INCY)

Several brokerages have updated their recommendations and price targets on shares of Incyte (NASDAQ: INCY) in the last few weeks:

• 12/8/2025 – Incyte had its price target raised by analysts at Morgan Stanley from $86.00 to $92.00. They now have an “equal weight” rating on the stock.
• 12/8/2025 – Incyte had its price target raised by analysts at Wells Fargo & Company from $97.00 to $116.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – Incyte was given a new $121.00 price target on by analysts at Mizuho. They now have an “outperform” rating on the stock.
• 12/8/2025 – Incyte was upgraded by analysts at Mizuho from a “neutral” rating to an “outperform” rating. They now have a $121.00 price target on the stock, up previously from $90.00.
• 11/24/2025 – Incyte had its price target raised by analysts at Barclays PLC from $101.00 to $115.00. They now have an “overweight” rating on the stock.
• 11/10/2025 – Incyte was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 11/4/2025 – Incyte had its price target raised by analysts at Piper Sandler from $82.00 to $102.00. They now have an “overweight” rating on the stock.
• 11/3/2025 – Incyte was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating. They now have a $125.00 price target on the stock.
• 11/1/2025 – Incyte was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 10/29/2025 – Incyte had its price target raised by analysts at Royal Bank Of Canada from $81.00 to $84.00. They now have a “sector perform” rating on the stock.
• 10/29/2025 – Incyte had its price target raised by analysts at Wells Fargo & Company from $89.00 to $97.00. They now have an “overweight” rating on the stock.
• 10/29/2025 – Incyte had its price target raised by analysts at Barclays PLC from $90.00 to $101.00. They now have an “overweight” rating on the stock.
• 10/29/2025 – Incyte had its “hold” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $93.00 price target on the stock, up previously from $79.00.
• 10/18/2025 – Incyte was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.

Insider Transactions at Incyte

In other news, EVP Sheila A. Denton sold 598 shares of Incyte stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $101.36, for a total value of $60,613.28. Following the completion of the sale, the executive vice president directly owned 26,569 shares in the company, valued at approximately $2,693,033.84. The trade was a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Steven H. Stein sold 20,105 shares of Incyte stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $102.51, for a total value of $2,060,963.55. Following the completion of the transaction, the executive vice president directly owned 63,129 shares of the company’s stock, valued at $6,471,353.79. This represents a 24.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 26,891 shares of company stock worth $2,720,766 in the last 90 days. Corporate insiders own 17.80% of the company’s stock.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.